Advancing a novel product pipeline of neurology therapies

View Product Pipeline

Advancing a novel product pipeline of neurology therapies

View Product Pipeline
About

We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.

Our novel product pipeline addresses areas of high unmet medical need, with a focus on epilepsy.

Read More

Product Pipeline


Preclinical
Phase 1
Phase 2
Phase 3
Approved

XEN1101

for Adult Focal Epilepsy
X-TOLE Clinical Trial

XEN1101

for Major Depressive Disorder (MDD)
Investigator-led Phase 2 POC study Collaboration with Mount Sinai

XEN1101

for MDD
Company-sponsored Phase 2 POC study

XEN496

for Orphan Pediatric Epilepsy (KCNQ2-DEE)
EPIK Clinical Trial

XEN007

for Pediatric Absence Epilepsy
Investigator-led Phase 2 POC study Absence Epilepsy

NBI-921352

for Rare Pediatric Epilepsy: SCN8A-DEE
Partnered with Neurocrine Biosciences

NBI-921352

for Focal-Onset Seizures in Adults
Partnered with Neurocrine Biosciences

FX301

for Post-Operative Pain
Partnered with Flexion Therapeutics


Investors

Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events

View Investor Area
Our Management

Learn more about Xenon's management group

View Management
Careers

See current career opportunities

View Careers